OPRX - OptimizeRx: Exponential Growth Drives The Valuation Cheaper
2024-03-22 19:46:57 ET
Summary
- OptimizeRx is experiencing exponential topline growth, but the market has not reacted to their stellar guidance, presenting a potential opportunity for a valuation re-rate in 2024.
- OptimizeRx provides a software suite called Dynamic Audience Activation Platform (DAAP) that improves the reach of drug distributors to physicians and patients through AI-based and direct messaging technologies.
- The acquisition of Medicx is expected to boost OptimizeRx's revenue growth and improve offerings to existing customers, potentially leading to a 30% upside potential in stock price.
...
OptimizeRx: Exponential Growth Drives The Valuation Cheaper